170 related articles for article (PubMed ID: 34666841)
1. Initial validation of a self-report questionnaire based on the Theoretical Domains Framework: determinants of clinician adoption of a novel colorectal cancer screening strategy.
Zhu X; Lee MK; Weiser E; Griffin JM; Limburg PJ; Finney Rutten LJ
Implement Sci Commun; 2021 Oct; 2(1):119. PubMed ID: 34666841
[TBL] [Abstract][Full Text] [Related]
2. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.
Finney Rutten LJ; Parks PD; Weiser E; Fan C; Jacobson DJ; Jenkins GD; Zhu X; Griffin JM; Limburg PJ
Mayo Clin Proc; 2022 Jan; 97(1):101-109. PubMed ID: 34920895
[TBL] [Abstract][Full Text] [Related]
3. Barriers to utilization of three colorectal cancer screening options - Data from a national survey.
Zhu X; Parks PD; Weiser E; Jacobson DJ; Limburg PJ; Finney Rutten LJ
Prev Med Rep; 2021 Dec; 24():101508. PubMed ID: 34401220
[TBL] [Abstract][Full Text] [Related]
4. Measuring determinants of implementation behavior: psychometric properties of a questionnaire based on the theoretical domains framework.
Huijg JM; Gebhardt WA; Dusseldorp E; Verheijden MW; van der Zouwe N; Middelkoop BJ; Crone MR
Implement Sci; 2014 Mar; 9():33. PubMed ID: 24641907
[TBL] [Abstract][Full Text] [Related]
5. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
[No Abstract] [Full Text] [Related]
6. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
7. Provider communication contributes to colorectal cancer screening intention through improving screening outcome expectancies and perceived behavioral control.
Zhu X; Squiers L; Helmueller L; Madson G; Southwell BG; Alam S; Finney Rutten LJ
Soc Sci Med; 2024 Jan; 340():116397. PubMed ID: 38043438
[TBL] [Abstract][Full Text] [Related]
8. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort.
Miller-Wilson LA; Rutten LJF; Van Thomme J; Ozbay AB; Limburg PJ
Int J Colorectal Dis; 2021 Nov; 36(11):2471-2480. PubMed ID: 34019124
[TBL] [Abstract][Full Text] [Related]
9. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a medicaid population.
Miller-Wilson LA; Finney Rutten LJ; Van Thomme J; Burak Ozbay A; Laffin J; Limburg P
Prev Med Rep; 2022 Dec; 30():102032. PubMed ID: 36531112
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate Multi-Target Stool DNA Use for Colorectal Cancer Screening: Risks, Compliance, and Outcomes.
Lazar NJ; Khreisat A; AlKloub R; Al-Hillan A; Duffy M
Cureus; 2023 Jun; 15(6):e40506. PubMed ID: 37397671
[TBL] [Abstract][Full Text] [Related]
12. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
[TBL] [Abstract][Full Text] [Related]
13. Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.
Finney Rutten LJ; Jacobson RM; Wilson PM; Jacobson DJ; Fan C; Kisiel JB; Sweetser S; Tulledge-Scheitel SM; St Sauver JL
Mayo Clin Proc; 2017 May; 92(5):726-733. PubMed ID: 28473037
[TBL] [Abstract][Full Text] [Related]
14. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness.
Berger BM; Schroy PC; Dinh TA
Clin Colorectal Cancer; 2016 Sep; 15(3):e65-74. PubMed ID: 26792032
[TBL] [Abstract][Full Text] [Related]
15. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
16. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
17. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
18. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population.
Ebner D; Kisiel J; Barnieh L; Sharma R; Smith NJ; Estes C; Vahdat V; Ozbay AB; Limburg P; Fendrick AM
J Med Econ; 2023; 26(1):1219-1226. PubMed ID: 37752872
[TBL] [Abstract][Full Text] [Related]
20. PPV and Detection Rate of mt-sDNA Testing, FIT, and CT Colonography for Advanced Neoplasia: A Hierarchic Bayesian Meta-Analysis of the Noninvasive Colorectal Screening Tests.
Pickhardt PJ; Correale L; Hassan C
AJR Am J Roentgenol; 2021 Oct; 217(4):817-830. PubMed ID: 33703913
[No Abstract] [Full Text] [Related]
[Next] [New Search]